LarryLSchlabachMD

Oncology • Chattanooga, TN

Oncologist at Erlanger Health System

Join to view full profile

Dr. Schlabach is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Schlabach's full profile

Already have an account?

Office
1032 McCallie Ave
Ste 200
Chattanooga, TN 37403
Phone+1 423-752-5004

Fax+1 423-414-3834

Education & Training

University of Alabama Medical CenterFellowship, Hematology and Medical Oncology, 1991 - 1993
University of Tennessee College of Medicine at ChattanoogaResidency, Internal Medicine, 1987 - 1990
Wright State University Boonshoft School of MedicineClass of 1987

Certifications & Licensure

GA State Medical License 1995 - 2026
TN State Medical License 1988 - 2025
MN State Medical License 2022 - 2024
OH State Medical License 1993 - 2006
AL State Medical License 1991 - 1993

Clinical Trials

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Start of enrollment: 2012 Aug 08
Active, not recruiting
Phase 3
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Feb 04
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

29 citations
Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer.
Dana Backlund Cardin, Laura W. Goff, Chung I. Li, Yu Shyr, Charles Winkler
Cancer Medicine. 2014-06-01
18 citations
A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carbo...
Anshu K. Jain, Randall S. Hughes, Alan B. Sandler, Afshin Dowlati, Lee S. Schwartzberg
Journal of Thoracic Oncology. 2009-06-01
62 citations
Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer
John V. Heymach, David H. Johnson, Fadlo R. Khuri, Howard Safran, L. L. Schlabach
Annals of Oncology. 2004-08-01

Professional Memberships

American College of Physicians - ACP
Member